PRIMERA试验:类风湿关节炎个体化治疗策略的随机对照研究
PRIMERA多中心开放标签随机对照试验纳入308例未用过DMARD的早期类风湿关节炎患者,评估基于自身抗体分层选择一线DMARD并依据早期治疗反应快速强化治疗的个体化策略是否优于常规达标治疗。结果显示10个月时ts/bDMARD使用率两组无显著差异,平均DAS轨迹相似,个体化策略未显示优越性。
要点
- 按自身抗体状态分层选择一线DMARD并快速强化,未改善10个月ts/bDMARD使用率。
- 个体化策略与常规达标治疗的平均DAS轨迹相似,患者报告结局及不良事件无差异。
- 标准达标治疗基础上进行上述修改未带来额外临床获益。
核心结论
- 基于自身抗体状态分层选择初始DMARD并结合早期反应快速强化治疗,未产生优于常规达标治疗的临床结局。
研究设计与样本
- 多中心、开放标签、随机对照试验,纳入308例未用过DMARD的RA患者(符合2010 ACR/EULAR标准),按1:1随机分配至个体化策略组(152例)或常规治疗组(156例)。
主要发现
- 10个月时ts/bDMARD使用率个体化策略组为21%,常规治疗组为17%(单侧p=0.20)。
- 两组平均DAS轨迹相似(p=0.57)。
- 患者报告结局指标轨迹及不良事件未观察到差异。
关键数值与推荐
- 两组均遵循达标治疗策略,每3-4个月强化治疗直至DAS≤2.4。
- 个体化策略组:自身抗体阳性者起始MTX,阴性者起始羟氯喹,均联合肌注GC桥接;DMARD起始或强化后1个月若DAS>2.4可在第1和第4个月额外强化。
- 常规治疗组:无论自身抗体状态均起始MTX联合GC桥接,无额外强化。
临床怎么用
- 在标准达标治疗框架下,按自身抗体状态选择一线DMARD并早期快速强化,未显示额外获益,不支持常规采用该个体化策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Guidelines for early rheumatoid arthritis (RA) recommend starting methotrexate, with optional glucocorticoid (GC) bridging, followed by treat-to-target intensifications after at least 3 months (routine care). Given RA's heterogeneity, we evaluated a stratified treat-to-target approach (tailor-made approach) consisting of two modifications to routine care: first-line disease-modifying antirheumatic drug (DMARD) selection stratified by autoantibody status and rapid treatment intensifications guided by early treatment response (within 1 month). METHODS: This multicentre, open-label randomised controlled trial included adults with DMARD-naïve RA (2010 American College of Rheumatology/European Alliance of Associations for Rheumatology (EULAR) criteria) who were randomly assigned (1:1) to the tailor-made approach or routine care. Both arms followed a treat-to-target strategy, intensifying every 3-4 months until Disease Activity Score (DAS) ≤2.4. The tailor-made approach started MTX in autoantibody-positive patients and hydroxychloroquine in autoantibody-negative patients, both with intramuscular GC bridging. Additional intensifications at months 1 and 4 were allowed when DAS >2.4, 1 month after DMARD initiation or intensification, enabling treatment escalation before the standard 3-month reassessment. Routine care started MTX with GC bridging regardless of autoantibody status and without extra intensifications. The two primary outcomes were targeted synthetic/biologic (ts/b)DMARD use at 10 months and mean DAS over time; superiority required both to favour the tailor-made approach. RESULTS: In total, 308 included patients were randomised(152 tailor-made; 156 routine care). At 10 months, ts/bDMARD use was 21% in the tailor-made approach vs 17% in routine care (one-sided p=0.20). Mean DAS trajectories were similar (p=0.57). No differences were observed in mean patient-reported outcome measure trajectories or adverse events. CONCLUSION: Modifying the standard treat-to-target strategy, by stratifying the initial DMARD according to autoantibody status combined with rapidly intensifying therapy based on early treatment response, did not result in superior clinical outcomes. TRIAL REGISTRATION NUMBER: ISRCTN16170070.
引用
- Looijen AEM, Dag HH, Heutz JW, et al. Exploring possibilities towards PeRsonalIsed MEdicine in Rheumatoid Arthritis (PRIMERA): tailored modifications to standard treat-to-target management-a multicentre, randomised, open-label trial. RMD Open. 2026. PMID: 42624617. doi:10.1136/rmdopen-2026-007217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。